Article Text

Download PDFPDF
Rivastigmine three times daily improves cognition and response in Alzheimer’s disease

Statistics from Altmetric.com

Footnotes

  • Source of funding: Novartis Pharma AG, Basle, Switzerland.

Footnotes

  • MRF is a consultant for: Abbott, Accera, CoMentis/Anthenagen, Inc, Cephalon, Eisai Pharm, GlaxoSmithKline, Medivation, Memory Pharma., Merck, NeuroMolecular Pharm, Novartis, Octapharma Pharmaceuticals, Sanofi-Aventis, Shering Plough Research Institute, Talecris Biother; has received Grant support from: Eli Lilly, Novartis Pharm, Ono/Pharmanet and is on the Speakers bureau for: Forest Labs, Pfizer, Eisai and Novartis.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.